TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
| Status: | Withdrawn |
|---|---|
| Conditions: | Alzheimer Disease, Neurology, Diabetes |
| Therapuetic Areas: | Endocrinology, Neurology |
| Healthy: | No |
| Age Range: | 55 - 75 |
| Updated: | 12/31/2017 |
| Start Date: | December 2017 |
| End Date: | January 2020 |
The purpose of this project is to study brain imaging of a substance called tau, which is
found in brains of persons with Alzheimer's disease, using the Tau binder, 18F-THK-5351, for
live imaging of tau in the brain. The main goal of this proposal is to study whether diabetes
status (type 2 diabetes [referred to as diabetes] and pre-diabetes, compared with normal
glucose tolerance [NGT]), is associated with increased tau accumulation in the brain, one of
the culprits of Alzheimer's disease, in a community-based group of middle aged
Caribbean-Hispanics with a mean age of 63 years. The investigators propose to conduct tau
positron emission tomography (PET) imaging in 30 middle aged Hispanics.
found in brains of persons with Alzheimer's disease, using the Tau binder, 18F-THK-5351, for
live imaging of tau in the brain. The main goal of this proposal is to study whether diabetes
status (type 2 diabetes [referred to as diabetes] and pre-diabetes, compared with normal
glucose tolerance [NGT]), is associated with increased tau accumulation in the brain, one of
the culprits of Alzheimer's disease, in a community-based group of middle aged
Caribbean-Hispanics with a mean age of 63 years. The investigators propose to conduct tau
positron emission tomography (PET) imaging in 30 middle aged Hispanics.
The burden of late onset Alzheimer's dementia (LOAD) and its antecedents is increasing
without known prevention or cure, and diabetes seems to be one of the strongest risk factors.
The predominating causal model in Alzheimer's disease (AD) research is based on the amyloid
hypothesis, which posits that amyloid (A) deposition in the brain causes synaptic dysfunction
resulting in early memory deficits and progression to mild cognitive impairment (MCI) and
dementia. Tau has also gained increasing interest as an AD pathology feature, biomarker, and
treatment target.
There are no known curative or preventive measures for LOAD. One of the strongest potential
LOAD risk factors is type 2 diabetes, an abnormal elevation of blood glucose associated with
microvascular and macrovascular complications including cerebrovascular disease. Many studies
have reported an association of diabetes with dementia, including LOAD and vascular dementia
(VD). Most studies have found that diabetes is associated with an increased risk of both LOAD
and VD, with a stronger association for VD compared with LOAD. Thus, this study focuses on
the relation of diabetes, pre-diabetes, and elevated glucose, with AD.
without known prevention or cure, and diabetes seems to be one of the strongest risk factors.
The predominating causal model in Alzheimer's disease (AD) research is based on the amyloid
hypothesis, which posits that amyloid (A) deposition in the brain causes synaptic dysfunction
resulting in early memory deficits and progression to mild cognitive impairment (MCI) and
dementia. Tau has also gained increasing interest as an AD pathology feature, biomarker, and
treatment target.
There are no known curative or preventive measures for LOAD. One of the strongest potential
LOAD risk factors is type 2 diabetes, an abnormal elevation of blood glucose associated with
microvascular and macrovascular complications including cerebrovascular disease. Many studies
have reported an association of diabetes with dementia, including LOAD and vascular dementia
(VD). Most studies have found that diabetes is associated with an increased risk of both LOAD
and VD, with a stronger association for VD compared with LOAD. Thus, this study focuses on
the relation of diabetes, pre-diabetes, and elevated glucose, with AD.
Inclusion Criteria:
- All persons who have undergone magnetic resonance imaging (MRI) and amyloid PET
already, or those who prospectively are deemed eligible for the parent study covered
under protocol AAAQ2950, will be approached for participation.
Exclusion Criteria:
- Person who are not participating in the MRI and amyloid PET under protocol AAAQ2950
We found this trial at
1
site
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
